Blockchain and Crypto Treasury Strategies Revolutionizing Biomedical Research Funding

Biomedical Firms Embrace Blockchain for Research Funding

The pharmaceutical industry is undergoing a radical transformation in research funding, as biomedical and scientific companies are turning to blockchain technology and crypto treasury strategies to finance their research. This shift aims to bypass traditional funding structures that often delay life-saving cures by decades.

Portage Biotech: A Pioneering Example

One example is Portage Biotech, a biomedical technology company, which pivoted in September to become a Toncoin (TON) treasury company. The company relies on generating operating revenues by staking TON to secure the network and investing in Telegram ecosystem projects, including games and mini-apps.

Brittany Kaiser, CEO of AlphaTON, told Cointelegraph that the company will allocate a portion of the revenue from operating activities and the capital appreciation of TON to fund cancer research. She added that the company is exploring real-world asset tokenization (RWA) as an alternative funding mechanism to decentralize scientific development and remove financial and access barriers to research funding inherent in the traditional system.

“We're doing research into the best case studies and what has worked and what hasn't, from tokenization of the intellectual property, to tokenization of equity of the company that owns the research, to tokenizing future profits of the research,” she said.

A Competitive Edge

Kaiser and Anthony Scaramucci, strategic advisor to AlphaTON, emphasized that biomedical research as an operating vertical sets the company apart from other digital asset treasuries, which often lack operating businesses. “Most cryptocurrency treasury companies take over the shell and eliminate the primary aspects of the original business, but this is a new case because there are very valuable assets in the shell,” Scaramucci told Cointelegraph.

Ideosphere Explores Prediction Markets

Ideosphere, a decentralized science startup, is exploring funding early-stage scientific research through prediction markets. Prediction market platforms act as crowdsourced intelligence and voting mechanisms.

Rei Jarram, co-founder and head of technology at Ideosphere, told Cointelegraph, “If you can create prediction markets around early stage research, you can make those markets a marketplace of ideas that will actually bring the money in.”

“Researchers can put forward hypotheses that they are working on, and traders can speculate on it, and the spread goes to the researcher,” he added.

Bio Protocol Secures Funding

In September, Bio Protocol, a decentralized science platform combining artificial intelligence, blockchain, and community participation in drug discovery research, secured $6.9 million in funding from Web3 company Animoca Brands and the Maelstrom fund.

Arthur Hayes, founder of Maelstrom, said the platform has the potential to become a full-fledged “AI-native research market” that can change the way scientific research is conducted.